Ramsey Homsany, co-founder and president of Octant Bio, sits down with Neil to discuss the company’s efforts to tackle complex diseases with next-generation small molecule drugs by harnessing synthetic biology to better understand the biochemical mechanisms of its targets, his unusual path to leadership of a biotechnology company, and Octant’s collaboration with Bristol Myers Squibb to apply its platform technologies to a set of inflammation-related pathways.
